What is the recommended diagnostic work‑up and management for Barlow’s disease (severe myxomatous mitral valve prolapse)?

Barlow's Disease: Diagnostic Work-Up and Management

Barlow's disease requires comprehensive echocardiographic assessment with transthoracic echocardiography as first-line imaging, followed by surgical referral to an experienced mitral valve surgeon at a high-volume center when severe mitral regurgitation develops, as these complex bileaflet myxomatous cases demand specialized surgical expertise for optimal repair outcomes.

Diagnostic Work-Up

Initial Echocardiographic Assessment

Transthoracic echocardiography (TTE) is your primary diagnostic tool 1, 2. You need to establish:

Severity of Mitral Regurgitation:

• Quantitative measurements are essential—use effective regurgitant orifice area (EROA ≥0.40 cm²), regurgitant volume (≥60 mL), and regurgitant fraction (≥50%) 2
• Vena contracta width ≥0.7 cm indicates severe MR 1, 2
• Color Doppler jet area >40% of left atrium suggests severe disease 2
• Critical caveat: Color Doppler can overestimate MR with high blood pressure or underestimate it with high LA pressures 1

Valve Morphology Specific to Barlow's:

• Bileaflet prolapse >2 mm above the mitral annulus 3, 4
• Excess myxomatous tissue with billowing leaflets 1
• Leaflet thickening ≥3 mm 3
• Severe annular dilatation 3
• Look for mitral annular disjunction—an important arrhythmogenic substrate 4, 5

Left Ventricular Assessment:

• LV ejection fraction (remember: "normal" in MR is ~70%, so concern arises when LVEF approaches 60%) 2
• LV end-systolic dimension (≥40 mm is a trigger for intervention) 2
• LV end-diastolic dimensions for remodeling assessment 2

Pulmonary Artery Pressure:

• PA systolic pressure ≥50 mm Hg worsens prognosis and may trigger intervention 1, 2

Advanced Imaging

Transesophageal Echocardiography (TEE):

• Use when TTE is inadequate or for surgical planning 1
• Better identifies complex anatomic features including clefts and chordal rupture (though it can miss some—TEE failed to identify clefts in 2/7 cases and chordal rupture in 4/31 in one series) 3
• Important: Anesthesia and reduced pressure during TEE may significantly reduce MR severity compared to awake TTE 1

Cardiac Magnetic Resonance (CMR):

• Gold standard for LV volumes and function 4
• Critical for risk stratification: Detects myocardial fibrosis via late gadolinium enhancement (typically at basal inferolateral wall and papillary muscles) 4, 5
• Fibrosis detection is crucial as it represents arrhythmogenic substrate 4, 5
• Use T1 mapping for diffuse fibrosis assessment 4, 5

Genetic and Family Screening

Barlow's disease shows autosomal dominant inheritance with age and sex-dependent expression 6, 7. Screen all first-degree relatives with echocardiography 6. Linkage to chromosome 16p11.2-p12.1 has been established, though genetic causes remain largely elusive 6, 7.

Risk Stratification for Sudden Cardiac Death

This is increasingly recognized as a critical complication, particularly in young women with bileaflet prolapse 8, 5. Look for:

• T-wave inversion in inferior leads 5
• Polymorphic premature ventricular contractions 5
• Mitral annular disjunction 4, 5
• Myocardial fibrosis on CMR (macro or diffuse) 4, 5
• Hypercontractility patterns 5
• Note: Severe MR is NOT necessarily present in those at highest arrhythmic risk 5

Management Algorithm

Asymptomatic Patients with Severe MR (Stage C)

Surgical Referral Triggers 2:

• LVEF ≤60% (Stage C2) 2
• LV end-systolic dimension ≥40 mm (Stage C2) 2
• New-onset atrial fibrillation 8
• Pulmonary hypertension (PA systolic pressure ≥50 mm Hg) 2

Even if above thresholds not met, consider early referral if high repair probability exists 2.

Symptomatic Patients with Severe MR (Stage D)

Immediate surgical referral is indicated 2. Symptoms include decreased exercise tolerance or exertional dyspnea 2.

Surgical Approach and Referral

Critical recommendation: Patients with Barlow's disease require referral to experienced mitral valve surgeons at high-volume institutions 1. This is non-negotiable—Barlow's represents the most complex end of the degenerative MR spectrum 1.

Surgical Techniques for Barlow's 1:

1. Sliding leaflet valvuloplasty with annuloplasty ring for diffuse posterior leaflet myxomatous disease 1
2. Nonresection techniques using PTFE neochord reconstruction for bileaflet prolapse 1
3. Extensive posterior leaflet resection and remodeling when needed 1
4. Techniques to prevent systolic anterior motion when echocardiographic predictors present 1

Repair vs. Replacement: Valve replacement should only occur if repair has been attempted and failed 1. Repair is strongly preferred given the complex but reparable nature of Barlow's pathology 9.

Minimally Invasive Surgery: Equivalent safety and efficacy to sternotomy in experienced centers, with faster recovery 9. However, there is a definite learning curve—if MIS is desired, refer to centers with extensive MIS mitral valve experience 9.

Surveillance for Non-Surgical Candidates

• Serial TTE every 6-12 months for asymptomatic severe MR 2
• Annual TTE for moderate MR or Stage B disease 2
• Consider exercise echocardiography if symptom status unclear 1

Common Pitfalls

1. Underestimating complexity: Barlow's is NOT simple posterior leaflet prolapse—it involves bileaflet pathology, annular dilatation, and often requires multiple repair techniques 1

2. Misinterpreting "normal" LVEF: An LVEF of 60-65% may represent LV dysfunction in the context of MR's favorable loading conditions 2

3. Ignoring arrhythmic risk: Young patients with bileaflet prolapse and MAD require arrhythmic risk stratification even without severe MR 4, 5

4. Inadequate surgical referral: Referring Barlow's patients to surgeons without extensive mitral repair experience increases failure rates 1

5. Missing functional prolapse: Some anterior leaflet prolapse in Barlow's is functional and resolves with annular stabilization alone—overtreatment adds unnecessary complexity 10